MyoGene Bio is a Finalist and Cydan Rare Disease Award Winner in the MassChallenge 2021 US Early Stage program

October 28, 2021

MyoGene was selected for the Cydan Rare Disease Award of $20,000 from the MassChallenge 2021 US Early Stage accelerator program. MyoGene participated in the program throughout the year, taking advantage of peer connections, mentorship, and the curriculum offered and was selected as a finalist. We thank the program, sponsor, and mentors for their support!

Read more here: 

https://masschallenge.org/news/36-masschallenge-startup-winners-named-from-the-2021-us-early-stage-cohort/